{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T05:22:11Z","timestamp":1739251331739,"version":"3.37.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.lungcan.2009.05.008","type":"journal-article","created":{"date-parts":[[2009,7,10]],"date-time":"2009-07-10T09:31:56Z","timestamp":1247218316000},"page":"94-98","source":"Crossref","is-referenced-by-count":7,"title":["Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer"],"prefix":"10.1016","volume":"68","author":[{"given":"Pasquale","family":"Comella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo E.","family":"Chiuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"De Cataldis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianfranco","family":"Filippelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Maiorino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Vessia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Cioffi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Mancarella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Putzu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ettore","family":"Greco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Palmeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Avallone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Franco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2009.05.008_bib1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advance non-small cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"NEJM"},{"key":"10.1016\/j.lungcan.2009.05.008_bib2","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2002.02.068","article-title":"Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer","volume":"20","author":"Scagliotti","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2009.05.008_bib3","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1200\/JCO.2003.03.195","article-title":"Three-arm randomized study of two cisplatinum-based regimens and paclitaxel plus gemcitabine in advanced non-small cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer","volume":"21","author":"Smit","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2009.05.008_bib4","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1200\/JCO.2002.12.112","article-title":"Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small cell lung cancer: a phase III randomized trial","volume":"20","author":"Kosmidis","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2009.05.008_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/annonc\/mdm430","article-title":"Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group","volume":"19","author":"Kosmidis","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2009.05.008_bib6","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1200\/JCO.2005.04.016","article-title":"Vinorelbine plus cisplatin versus docetaxel gemcitabine advanced non-small cell lung cancer. A phase III randomized trial","volume":"23","author":"Georgoulias","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2009.05.008_bib7","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S0140-6736(00)04644-4","article-title":"Platinum-based and non-platinum-based chemotherapy in advanced non-small cell lung cancer: a randomised multicentre trial","volume":"357","author":"Georgoulias","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2009.05.008_bib8","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/annonc\/mdi126","article-title":"Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small cell lung cancer: a phase III study addressing the case for cisplatin","volume":"16","author":"Pujol","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2009.05.008_bib9","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2003.06.099","article-title":"Gemcitabine plus vinorelbine versus cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small cell lung cancer: a phase III trial of the Italian GEMVIN investigators and the National Cancer Institute of Canada Clinical Trial Group","volume":"21","author":"Gridelli","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2009.05.008_bib10","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/annonc\/mdl396","article-title":"Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101)","volume":"18","author":"Comella","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2009.05.008_bib11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.critrevonc.2007.06.014","article-title":"Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic non-small cell lung cancer. A retrospective analysis of the Southern Italy Cooperative Oncology Group trials","volume":"65","author":"Comella","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.lungcan.2009.05.008_bib12","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.2005.03.045","article-title":"Platinum-based versus non-platinum-based chemotherapy in advanced non-small cell lung cancer. A meta-analysis of published literature","volume":"23","author":"D\u2019Addario","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2009.05.008_bib13","doi-asserted-by":"crossref","first-page":"4276S","DOI":"10.1158\/1078-0432.CCR-040010","article-title":"Pemetrexed (Alimta), a novel multitarget antineoplastic agent","volume":"10","author":"Adjei","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2009.05.008_bib14","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomised phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2009.05.008_bib15","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/annonc\/mdf115","article-title":"Phase II study of pemetrexed disodium (ALIMTA, LY231514), in chemonaive patients with advanced non-small cell lung cancer","volume":"13","author":"Clarke","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2009.05.008_bib16","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1200\/JCO.1999.17.4.1194","article-title":"Multitarget antifolate of LY231514 as first-line chemotherapy for patients with advanced non-small cell lung cancer: a phase II study-National Institute of Canada Clinical Trial Group","volume":"17","author":"Rusthoven","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2009.05.008_bib17","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/1097-0142(20010801)92:3<595::AID-CNCR1359>3.0.CO;2-D","article-title":"Phase II study of pemetrexed disodium, a multitarget antifolate, and cisplatin as first-line therapy in patients with advanced non-small cell lung carcinoma: a study of the National Institute of Canada Clinical Trials Group","volume":"92","author":"Shepherd","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2009.05.008_bib18","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1078-0432.690.11.2","article-title":"Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter randomized phase III trial","volume":"11","author":"Scagliotti","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2009.05.008_bib19","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1002\/cncr.21480","article-title":"Phase II of pemetrexed in combination with carboplatin in first-line treatment of advanced non-small cell lung cancer","volume":"104","author":"Zinner","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2009.05.008_bib20","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-na\u00efve patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2009.05.008_bib21","doi-asserted-by":"crossref","first-page":"000","DOI":"10.1634\/theoncologist.2008-0232","article-title":"The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies","volume":"14","author":"Scagliotti","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.lungcan.2009.05.008_bib22","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1158\/1078-0432.CCR-04-0218","article-title":"Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer","volume":"10","author":"Monnerat","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2009.05.008_bib23","doi-asserted-by":"crossref","first-page":"5929","DOI":"10.1200\/JCO.2005.13.953","article-title":"Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small cell lung cancer","volume":"23","author":"Ma","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2009.05.008_bib24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.lungcan.2006.04.005","article-title":"Administration of pemetrexed immediately following gemcitabine ad front-line therapy in advanced non-small cell lung cancer: a phase II trial","volume":"53","author":"Treat","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2009.05.008_bib25","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/annonc\/mdn715","article-title":"Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial","volume":"20","author":"West","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2009.05.008_bib26","doi-asserted-by":"crossref","unstructured":"Blakely LJ, Schwartzberg L, Keaton M, et al. A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and\/or elderly patients with stage IIIB\/IV non-small cell lung cancer. Lung Cancer 2009; doi:10.1016\/j.lungcan.2008.12.017.","DOI":"10.1016\/j.lungcan.2008.12.017"},{"key":"10.1016\/j.lungcan.2009.05.008_bib27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2009.05.008_bib28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lungcan.2009.05.008_bib29","first-page":"1375","article-title":"Randomized phase II clinical trials","volume":"69","author":"Simon","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.lungcan.2009.05.008_bib30","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2307\/2281868","article-title":"Non parametric estimation for incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.lungcan.2009.05.008_bib31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500209003092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500209003092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T21:52:34Z","timestamp":1739224354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500209003092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0169500209003092"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2009.05.008","relation":{},"ISSN":["0169-5002"],"issn-type":[{"type":"print","value":"0169-5002"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}